Schedule 13G ownership disclosure
Entrada Therapeutics Inc
Common Stock · CUSIP: 29384C108
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- JANUS HENDERSON GROUP PLC
Shares: 2,121,654 · Class: 5.6%
- Janus Henderson Biotech Innovation Master Fund Ltd
Shares: 1,884,826 · Class: 5.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001274173-25-000159
- Form type
- SCHEDULE 13G/A
- Filer
- Entrada Therapeutics, Inc.
- CIK
- CIK 1689375
- Filed
- May 14, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership